Sequential Therapy with Crizotinib and Alectinib in ALK-Rearranged Non-Small Cell Lung Cancer-A Multicenter Retrospective Study.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Alectinib and crizotinib have been approved for the therapy of NSCLC caused by anaplastic lymphoma kinase gene (ALK) rearrangement. The effect of alectinib or crizotinib on overall survival (OS) in patients with ALK-rearranged NSCLC remains unknown.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): J Thorac Oncol

Title: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer

Publisher: Elsevier BV

ISSN (Electronic): 1556-1380

ISSN (Print): 1556-0864

Publication date (Electronic): Feb 2017

Volume: 12

Issue: 2

Affiliations

[1 ] Respiratory Center, Matsusaka Municipal Hospital, Matsusaka, Japan.

[2 ] Department of Respiratory Medicine, Suzuka Central General Hospital, Suzuka, Japan.

[3 ] Department of Pulmonary Medicine, Mie Prefectural General Medical Center, Yokkaichi, Japan.

[4 ] Department of Immunology, Mie University Faculty and Graduate School of Medicine, Tsu, Japan.

[5 ] Department of Respiratory Medicine, Ise Red Cross Hospital, Ise, Japan.

[6 ] Department of Respiratory Medicine, Yokkaichi Municipal Hospital, Yokkaichi, Japan.

[7 ] Department of Pulmonary and Critical Care Medicine, Mie University, Tsu, Japan.

[8 ] Department of Immunology, Mie University Faculty and Graduate School of Medicine, Tsu, Japan. Electronic address: gabazza@doc.medic.mie-u.ac.jp.

[9 ] Mie University Center for Physical and Mental Health, Mie University, Tsu, Japan.

[10 ] Third Department of Internal Medicine, Wakayama Medical University, Wakayama, Japan.

Article

Publisher Item ID: S1556-0864(16)30701-8

DOI: 10.1016/j.jtho.2016.07.022

PubMed ID: 27498387

SO-VID: 3e99ccb6-d40b-4e97-884b-3ecf989c7b00

History

Keywords: Alectinib,Anaplastic lymphoma kinase inhibitor,Crizotinib,Non–small cell lung cancer,Overall survival,Sequential therapy

Data availability:

Keywords: Alectinib, Anaplastic lymphoma kinase inhibitor, Crizotinib, Non–small cell lung cancer, Overall survival, Sequential therapy

Sequential Therapy with Crizotinib and Alectinib in ALK-Rearranged Non-Small Cell Lung Cancer-A Multicenter Retrospective Study.

Read this article at

Abstract

Related collections

Inflamed lung in vitro co-culture models

Author and article information

Journal

Affiliations

Article

History

Comments

Comment on this article

Similar content 1,185

Cited by 18